Source: DGNews  |  Posted 3 years ago

BASEL, Switzerland -- June 30, 2008 -- Health Canada has authorised the marketing of ceftobiprole medocaril for injection (ZEFTERA) for the treatment of complicated skin and soft tissue infections including diabetic foot infections.

Ceftobiprole is the first approved broad-spectrum anti-methicillin-resistant Staphylococcus aureus (MRSA) antibiotic belonging to the cephalosporin class. It is specially designed to bind the penicillin-resistant targets in many Gram-positive bacteria of the cocci-type, resulting in bactericidal activity towards MRSA and penicillin-resistant Streptococcus pneumoniae.

Ceftobiprole as a single intravenous agent has demonstrated broad-spectrum activity against many other Gram-positive as well as Gram-negative bacteria, frequently associated with community and hospital-acquired infections.

SOURCE: Basilea Pharmaceutica Ltd.